Furthermore, SDF-1α might be the key reason forcEPC changes, and targeting SDF-1α/CXCR4 axis therapy or combining it with conventionalchemotherapy could improve the responses and outcomes of MM patients. This evidence concerns the gene CXCR4 and Miyoshi myopathy.